Spots Global Cancer Trial Database for Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
Official Title: Clinical Application of Efficacy Prediction Model Based on Epigenetics Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
Study ID: NCT05515796
Study Description
Brief Summary: immunotherapy，gastric cancer，rectal cancer，biomark
Detailed Description: To investigate the effect of Terelizumab (aka Tislelizumab) combined with XELOX in Neoadjuvant Therapy for gastrointestinal tumors. To explore new biomarkers that can predict the efficacy of combined immunotherapy, and to establish a clinical efficacy prediction model by means of bioinformatics to prospectively judge the efficacy and guide the follow-up individualized and accurate treatment.
Eligibility
Minimum Age: 19 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Army Medical Center, Chongqing, Other (Non U.s.), China
Contact Details
Name: wang bin
Affiliation: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
